刚刚！特朗普签了！直线拉升！

Core Viewpoint - The article discusses President Trump's executive order aimed at reducing prescription drug prices in the U.S., which led to a positive market reaction from pharmaceutical companies and a significant rise in U.S. stock indices [1][3]. Summary by Sections Executive Order Details - Trump signed an executive order to implement "Most Favored Nation" pricing for prescription drugs, aligning U.S. drug prices with those of other developed countries [3][5]. - The order aims to ensure that U.S. patients can purchase drugs at the lowest prices available globally, potentially reducing prices by 50% to 90% for some medications [5]. Market Reaction - Following the announcement, major pharmaceutical stocks such as Eli Lilly, Pfizer, and Novo Nordisk saw price increases of 2.86%, 3.64%, and 2.98% respectively [1][3]. - The U.S. stock market experienced a significant rally, with the Dow Jones rising over 1160 points (2.81%) and the Nasdaq gaining over 4% [1][7]. Broader Market Context - The article notes that the Nasdaq China Golden Dragon Index rose by 5.4%, indicating strong performance from Chinese concept stocks [1][7]. - Major tech stocks also surged, with Amazon up 8.07% and Meta up 7.92%, contributing to a technical bull market [7][8]. Implications for Pharmaceutical Companies - Analysts suggest that the vague wording of the executive order and lack of specific implementation details led to a positive interpretation by pharmaceutical companies, reducing their anticipated concerns [3][4]. - The order directs the U.S. Department of Health and Human Services to establish mechanisms for direct purchasing of drugs at "Most Favored" prices, bypassing intermediaries [3][4].